Scandinavian ChemoTech AB (publ)

OM:CMOTEC B Stock Report

Market Cap: SEK 34.3m

Scandinavian ChemoTech Past Earnings Performance

Past criteria checks 0/6

Scandinavian ChemoTech's earnings have been declining at an average annual rate of -12.5%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been declining at an average rate of 3.3% per year.

Key information

-12.5%

Earnings growth rate

20.0%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate-3.3%
Return on equity-175.1%
Net Margin-312.0%
Next Earnings Update04 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Scandinavian ChemoTech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:CMOTEC B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245-16160
30 Jun 245-17160
31 Mar 244-19190
31 Dec 233-21190
30 Sep 233-22280
30 Jun 232-23260
31 Mar 230-23180
31 Dec 220-23180
30 Sep 220-22180
30 Jun 220-22160
31 Mar 222-20170
31 Dec 213-18170
30 Sep 213-15120
30 Jun 213-12110
31 Mar 212-11110
31 Dec 201-12100
30 Sep 202-14150
30 Jun 202-14150
31 Mar 204-13150
31 Dec 195-12150
30 Sep 195-10110
30 Jun 196-9110
31 Mar 195-9120
31 Dec 185-8120
30 Sep 184-640
30 Jun 184-650
31 Mar 183-770
31 Dec 172-890
30 Sep 172-10110
30 Jun 172-8100
31 Mar 172-680
31 Dec 162-450
30 Sep 161-230
30 Jun 161-120
30 Jun 150000

Quality Earnings: CMOTEC B is currently unprofitable.

Growing Profit Margin: CMOTEC B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CMOTEC B is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.

Accelerating Growth: Unable to compare CMOTEC B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMOTEC B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: CMOTEC B has a negative Return on Equity (-175.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:02
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Scandinavian ChemoTech AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sebastian AnderssonRedeye
Martin WahlstromRedeye